LB Pharmaceuticals Inc
Research LB Pharmaceuticals Inc (LBRX) on Bullrun: market cap USD 1.40B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLBRX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.40B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 38.95M
- Free cash flow-USD 23.32M
Valuation Snapshot
latest market cap is USD 1.40B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 25.21M | -USD 35.26M | n/a | -3.13 | USD 250.17M | USD 3.57M | USD 301.31M |
| FY2024 | USD 0 | -USD 63.10M | -USD 53.82M | n/a | -176.15 | USD 22.98M | USD 3.70M | -USD 94.55M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.40B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 563.16M | n/a | n/a | n/a |
About LB Pharmaceuticals Inc
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is LB Pharmaceuticals Inc's market cap?
LB Pharmaceuticals Inc's market capitalization is USD 1.40B.
What does LB Pharmaceuticals Inc do?
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.